Bharat Parenterals Limited Q2 FY26 results deck summary

Results deck of 12 Nov 2025, summarised by AI from the filing.

Standalone revenue from operations ₹41.70 cr, down 35.30% YoY and 55.81% QoQ, due to export deferment and production break.

Key takeaways

1. Q2 FY26 revenue Standalone revenue from operations ₹41.70 cr, down 35.30% YoY and 55.81% QoQ, due to export deferment and production break.
2. FY26 guidance BPL maintains FY26 revenue growth guidance of 12–14% and expects EBITDA margins of 15–17%.
3. Growth driver Innoxel’s USFDA EIR and 7 new CMO deals with cumulative value USD 1.85 million support commercial supplies from Q1 FY27.

Original filing on BSE

Bharat Parenterals Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Results deck (5 Aug 2026)
• Q4 FY26: Earnings call (19 May 2026), Results deck (18 May 2026)
• Q3 FY26: Results deck (30 Jan 2026)
• Q2 FY26: Earnings call (12 Nov 2025), Results deck (12 Nov 2025)
• Q1 FY26: Results deck (28 Jul 2025)
• Q4 FY25: Earnings call (14 May 2025)